The consortium’s strategy is to create an AI-driven Structure-enabled Antiviral Platform (ASAP), using cutting-edge technology such as advanced structural biology, fragment screening, AI and machine learning, as well as computational chemistry on Folding@home, the world’s largest distributed computing platform to build a robust and open access antiviral discovery pipeline. Click to read more.
Developing a Cell Therapy for Parkinson’s Disease
AMSBIO reports upon a publication that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.
Image credit: AMS Bio
Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinson s disease consists of augmentation of dopamine levels in the brain via dopamine supplements or agonists or by inhibiting dopamine degradation. Treatment using this methodology is symptomatic but not long-lasting, and unfortunately has no neuroprotective effect. Cell therapy with grafts of human fetal tissue from the ventral mesencephalon have been carried out successfully, with multiple repo